Moneycontrol
Last Updated : Nov 12, 2018 09:55 AM IST | Source: Moneycontrol.com

Lupin gains 2% on EIR from USFDA without any observations

The inspection conducted in September 2018 concluded without any observations.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Share price of Lupin gained 2.5 percent intraday Monday on receiving EIR from USFDA.

The company has received (EIR) establishment inspection report post the completion of a pre-approval inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules, carried out by the USFDA at its Nagpur facility in Maharashtra.

The inspection conducted in September 2018 concluded without any observations.

The Nagpur facility is the company's latest site and manufactures Oral Solid Dosage products. The site also houses Lupin's state of the art injectable manufacturing facility.

Nilesh Gupta, Managing Director, Lupin said, "The receipt of the EIR for our Nagpur facility is a positive development as we continue our journey on meeting and exceeding global quality standards at all of our facilities."

At 09:48 hrs Lupin was quoting at Rs 872, up Rs 17.80, or 2.08 percent on the BSE.

For more market news, click here
First Published on Nov 12, 2018 09:55 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant